Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype.
复制标题

雄性BRCA1和BRCA2突变载体中的前列腺癌具有更具侵略性的表型。

DOI:
10.1038/sj.bjc.6604132
复制
发表时间:
2008-01-29
影响因子:
8.8
通讯作者:
Eeles, R.
Eeles, R.
中科院分区:
医学1区
文献类型:
--
作者:
Mitra, A.;Fisher, C.;Foster, C. S.;Jameson, C.;Barbachanno, Y.;Bartlett, J.;Bancroft, E.;Doherty, R.;Kote-Jarai, Z.;Peock, S.;Easton, D.;Eeles, R.

文献摘要

参考文献

被引文献

相似文献

在英国男性人群中,前列腺癌(PRCA)的患病率很高且呈上升趋势。尽管男性BRCA2和BRCA1突变携带者患PRCA的相对风险较高,但这些人群中这种恶性肿瘤的组织学特征尚未明确定义。我们报告了英国首批BRCA1和BRCA2突变携带PRCA的患者的组织病理学结果。从英国、爱尔兰和苏格兰的组织病理学实验室收集了20例BRCA1/2突变携带PRCA的组织病理学切片。根据年龄、分期和普通人群中诊断的PRCA病例的血清PSA水平,将这些病例与对照组相匹配。经组织病理学评估并按照现行常规标准重新分级后,发现BRCA1/2突变携带者的PRCA Gleason评分显著高于对照组(Gleason评分为8、9或10,P=0.012)。由于BRCA1/2突变携带者状态与更具侵袭性的疾病相关,因此它是PRCA结果的预后因素。针对这一人群的筛查可以在早期临床阶段发现疾病,因此可能是有益的。
There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly higher (Gleason scores 8, 9 or 10, P=0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial.
DOI: 10.1086/345310
发表时间: 2003-01-01
影响因子: 9.8
作者:
Edwards, SM;Kote-Jarai, Z;Eeles, RA
通讯作者: Eeles, RA
DOI: 10.1002/pros.20278
发表时间: 2005-10-01
期刊: PROSTATE
影响因子: 2.8
作者:
Horsburgh, S;Matthew, A;Trachtenberg, J
通讯作者: Trachtenberg, J
DOI: 10.1016/j.ijrobp.2003.10.014
发表时间: 2004-06-01
影响因子: 7
作者:
King, CR;McNeal, JE;Presti, JC
通讯作者: Presti, JC
DOI: 10.1093/jnci/90.15.1138
发表时间: 1998-08-05
影响因子: 10.3
作者:
Lakhani, SR;Jacquemier, J;Easton, DF
通讯作者: Easton, DF
DOI: 10.1093/jnci/djm005
发表时间: 2007-06-20
影响因子: 10.3
作者:
Tryggvadottir, Laufey;Vidarsdottir, Linda;Tulinius, Hrafn
通讯作者: Tulinius, Hrafn